CMR Surgical Timeline

Events

• 2026-10-12 - Market Signal - CMR Surgical agrees proposed Stryker investment and U.S. alliance - The agreement gives Stryker an exclusive option to acquire all CMR Surgical equity in the future. Stryker will serve as exclusive U.S. sales agent for the Versius portfolio. CMR Surgical will continue product development and commercialization outside the… - source: via.ritzau.dk
• 2026-07-22 - Demonstration - CMR Surgical announces an NVIDIA simulation workflow for Versius Plus - The workflow uses NVIDIA Isaac for Healthcare’s Medical Physics Simulation framework and Cosmos-H-Dreams. CMR planned to showcase the simulation at the Society of Robotic Surgery conference in Florida on July 23–26, 2026. The simulation is for research and… - source: us.cmrsurgical.com
• 2026-07-09 - Regulatory - FDA records an open Class II recall for two Versius surgeon consoles - The recall covers two V-SS-1020 consoles running Pratchett 1 version 62.1 that were distributed in California. The firm initiated the recall on June 9, 2026 and the corrective action is to notify customers and configure secure boot on the affected consoles.… - source: accessdata.fda.gov
• 2026-04-29 - Regulatory - CMR Surgical submits Versius Plus 510(k) for benign gynecology - The submission seeks clearance for benign procedures including total hysterectomy, oophorectomy and salpingectomy. CMR said the filing builds on global clinical experience and supports its U.S. market expansion. This is a premarket submission, not an FDA… - source: us.cmrsurgical.com
• 2026-03-26 - Production Milestone - CMR Surgical reports 45,000 patients treated with Versius - The milestone spans general, colorectal, urology, gynaecology and thoracic procedures. CMR announced the total as it began introducing Versius Plus to U.S. surgeons after FDA clearance. Versius had been adopted by hospitals across more than 30 countries at… - source: us.cmrsurgical.com
• 2026-01-08 - Regulatory - CMR Surgical receives CE and UKCA marks for Versius paediatric surgery - The marks cover abdominal surgery in children and infants under 18. CMR said this was its first regulatory clearance for treating children. The release highlights Versius’ compact, modular design and small instruments for paediatric anatomy. - source: globenewswire.com
• 2025-12-16 - Regulatory - FDA clears Versius Plus for adult cholecystectomy - The clearance covers robotically assisted cholecystectomy in adults aged 22 and older. Versius Plus remains surgeon-controlled and uses modular bedside arm units with an open console. CMR said U.S. commercialisation would begin in 2026. - source: us.cmrsurgical.com
• 2025-04-04 - Funding - CMR Surgical closes financing round of more than $200M - The round closed with participation from existing investors and new investor Trinity Capital. CMR said proceeds will support global commercialization of Versius, with a focus on the U.S., and continued product development. CMR said Versius had completed more… - source: us.cmrsurgical.com
• 2025-01-14 - Executive Hire - CMR Surgical appoints Massimiliano Colella as Chief Executive Officer - Colella joined CMR as Chief Commercial Officer in 2023. He had served as Interim Chief Executive Officer since October 2024. The appointment placed Colella as CEO and Board member as CMR continued expanding Versius globally. - source: us.cmrsurgical.com
• 2024-10-14 - Regulatory - CMR Surgical receives U.S. FDA marketing authorization for Versius - The authorization was granted through the FDA De Novo process for a multi-port soft-tissue robotic-assisted surgical device. The stated U.S. indication was cholecystectomy for adults 22 and older who are eligible for soft-tissue minimal-access surgery. The… - source: us.cmrsurgical.com
• 2024-09-03 - Org Change - CMR Surgical strengthens its senior team - Bauman joined CMR’s executive leadership team with legal, corporate finance and mergers-and-acquisitions experience. Paknad joined to support global commercial efforts and brought experience in soft-tissue surgical robotics. The appointments strengthened… - source: us.cmrsurgical.com
• 2024-07-15 - Executive Hire - CMR Surgical appoints Daniel Moore as Non-Executive Chairman - Moore’s role is to lead the CMR Surgical Board. The appointment places the Chair alongside CMR’s Board members and executive leadership. CMR said the leadership team would continue working to bring Versius to more hospitals and patients. - source: us.cmrsurgical.com
• 2021-06-28 - Funding - CMR Surgical closes $600M Series D at $3B valuation - New investors included RPMI Railpen, Tencent and Chimera. LGT, Lightrock, Watrium, Cambridge Innovation Capital, PFM Health Sciences and GE Healthcare also participated. The capital supports global commercialization of Versius and development of CMR’s… - source: globenewswire.com